Drug Profile
HTL 0016878
Alternative Names: HTL-0016878; NBI-1117568Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Neurocrine Biosciences; Sosei Heptares
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action Muscarinic M4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Schizophrenia
- No development reported Alzheimer's disease
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Schizophrenia in United Kingdom (PO)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in United Kingdom (PO, Liquid)
- 12 Oct 2022 Phase-II clinical trials in Schizophrenia in USA (PO) (NCT05545111)